Pegasys
+ Copegus
peginterferon
alfa-2a + Copegus (ribavirin) 
PEGASYS
Medication Guide
Pegasys
Product Information
Copegus
Medication Guide
Copegus
Product Information
|
 Articles
on Pegasys + Copegus |
• | IDEAL
Researchers Look at Predictors of Response to Pegylated
Interferon plus Ribavirin, including Race/ethnicity and Anemia
- 11/07/2008 |
• | Safety and antiviral activity of BI 201335,
a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis
C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
-
11/05/2008 |
• | Safety and antiviral activity of BI 201335,
a new HCV NS3 protease inhibitor, in combination therapy with peginterferon
alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced
patients with chronic hepatitis C genotype 1 infection -
11/05/2008 |
• | Hematologic
Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles
of Peginterferon alfa/Ribavirin
-
11/05/2008 |
• | Treatment-Related
Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon
(PEG)/Ribavirin (RBV): Results From the IDEAL Study -
11/05/2008 |
• | Response
to Pegylated Interferon plus Ribavirin in Asian
Patients with Genotype 1 Chronic Hepatitis C - 10/21/2008 |
• | Pegylated Interferon plus Ribavirin
Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals -
10/17/08 |
• | 24
Weeks of Pegylated Interferon plus Ribavirin
May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with
Rapid Response - 10/14/08 |
• | Individuals
with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin
- 10/14/08 |
• | Higher
Doses of Pegylated Interferon and Ribavirin
May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis
C - 10/10/08 |
• | Sustained
Virological Response to Pegylated Interferon plus Ribavirin
for Chronic Hepatitis C Does Not Always Prevent Hepatocellular
Carcinoma - 10/10/08 |
• | Genetic
Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C
Trial - 9/09/2008 |
• | Insulin-sensitizing
Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated
Interferon plus Ribavirin - 8/29/2008 |
• | Are
HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment
with Pegylated Interferon plus Ribavirin
- 8/19/2008 |
• | Body
Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated
with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
- 8/12/2008 |
• | Eight
Weeks of Pegylated Interferon plus Ribavirin
for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
- 8/05/2008 |
• | Telaprevir
plus Pegylated Interferon and Ribavirin
Produces Rapid Response and Is Well Tolerated in 28-day Study -
7/22/08 |
• | Comparison
of the Pegylated Interferons Pegasys and PegIntron
for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials -
7/18/08 |
• | 12-
Versus 24-week Treatment with Pegylated Interferon plus
Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients -
7/11/08 |
• | Studies
Explore Lower Doses of Pegylated Interferon and Ribavirin
for People with Hepatitis C Virus Genotypes 2 or 3 -
7/08/08 |
• | European
Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid
Responders with HCV Genotypes 2 or 3 and Low Viral Load -
7/04/08 |
• | Pegylated
Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding
Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial -
6/03/08 |
• | Platelet
Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in
Prior Non-Responders (EPIC 3) -
5/20/08 |
• | Rapid Virologic Response to Peginterferon
alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained
Virologic Response and Relapse -
5/20/08 |
• | Amino
Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated
Interferon/ribavirin in Genotype 1b Patients - 5/20/08 |
• | Pegylated Interferon plus Ribavirin
Is Effective for Patients with HCV-HBV Coinfection -
5/09/08 |
• | Factors
Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated
Interferon plus Ribavirin -
5/06/08 |
• | Factors
Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated
Interferon plus Ribavirin -
5/06/08 |
• | Cyclophilin
Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with Pegylated Interferon
-
5/06/08 |
• | IDEAL
Study Finds Higher End-of-treatment Response with Pegasys, but Lower Relapse Rate
with PegIntron -
5/02/08 |
• | Milk
Thistle (Silibinin) Shows Potent Antiviral Activity in Hepatitis C Patients Who Are Non-responders
to Pegylated Interferon/Ribavirin -
5/02/08 |
• | R7128
Demonstrates Potent Anti-HCV Activity in Combination with Pegylated
Interferon/Ribavirin; Ongoing Trial to be Expanded -
4/29/08 |
• | Large
HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance
Adds Little Benefit (HALT-C) -
4/29/08 |
• | Pegylated Interferon Maintenance Demonstrates
Benefits for Hepatitis C Patients with Portal
Hypertension -
4/29/08 |
• | HCV
Polymerase Inhibitor R1626 Produces Good Response with Pegylated
Interferon/Ribavirin and Has High Barrier to Resistance -
4/29/08 |
• | How
Ideal Is the IDEAL Trial?
|
FDA-approved
Combination Therapies for Chronic HCV Infection
